Products marketed as exosomes or extracellular vesicles are offered by injection, IV infusion, inhalation, or after skin procedures. FDA states there are currently no FDA-approved exosome products, and serious adverse events have been reported.
Exosomes are one class of extracellular vesicles released by cells and involved in intercellular signaling. Laboratory research studies their cargo and potential uses. A commercial vial labeled “exosomes,” however, is not defined by the concept alone: source, donor, cell culture, purification, particle characterization, sterility, potency, contaminants, storage, dose, and route all matter.
No FDA-approved exosome products
FDA states that there are currently no FDA-approved exosome products. Products intended to treat disease or alter body structure or function generally require review as drugs and biological products. Calling them acellular, cell-free, topical, or derived from stem cells does not create an exemption.
Serious adverse events have been reported
FDA issued public safety notifications after serious adverse events associated with unapproved products marketed as exosomes. Risks can arise from contamination, donor material, manufacturing inconsistency, unknown cargo, immune effects, dose, and administration route.
Route changes risk
Evidence limits
Cell-culture and animal findings cannot establish that a commercial human product regenerates joints, restores hair, rejuvenates skin, treats long COVID, improves cognition, or slows aging. Results from one source and manufacturing process do not transfer to another.
Clinical trial verification
A legitimate trial should identify product manufacturing, sponsor, IND status when required, ethics review, protocol, eligibility, safety monitoring, and follow-up. A ClinicalTrials.gov listing or clinic registration is not FDA approval.
Ask for the product label, source, manufacturer, lot, certificate and methods—not just a certificate of analysis—plus sterility/endotoxin data, FDA or IND status, trial sponsor, IRB, route, dose, and adverse-event plan. Do not apply or inject an unknown product into freshly injured skin.
There is no standardized recovery because products and routes are unapproved and heterogeneous. Fever, chills, rash, breathing difficulty, severe pain, neurologic change, joint swelling, drainage, or worsening skin injury requires prompt evaluation.
Contamination, serious infection, inflammatory or immune reaction, allergy, clot or embolic events, organ injury, product inconsistency, unknown biological cargo, injection injury, pulmonary harm from inhalation, and delayed effective treatment. Long-term risks are not defined.
FDA. Public Safety Notification on Exosome Products.
https://www.fda.gov/vaccines-blood-biologics/safety-availability-biologics/public-safety-notification-exosome-productsFDA Consumer Alert: Stem Cells and Exosomes.
https://www.fda.gov/vaccines-blood-biologics/consumers-biologics/consumer-alert-regenerative-medicine-products-including-stem-cells-and-exosomesThe Biology, Function, and Biomedical Applications of Exosomes.
https://doi.org/10.1126/science.aau6977FDA. Regulatory Considerations for Microneedling Products.
https://www.fda.gov/media/107708/download© 2026 Longevity Clinic Finder. All rights reserved.
Designed by SMBPulse
Frequency
No evidence-based wellness, orthopedic, aesthetic, or anti-aging schedule exists.
Participants in properly overseen clinical research with a defined investigational product and indication. Commercial exosome treatment outside legitimate trials lacks an FDA-approved product.
Explore nearby clinics, compare profiles, and find providers offering this treatment.
Find Clinics Near You© 2026 Longevity Clinic Finder. All rights reserved.
Designed by SMBPulse
Your Privacy Choices